William Towner to Hepatitis C, Chronic
This is a "connection" page, showing publications William Towner has written about Hepatitis C, Chronic.
Connection Strength
0.762
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Score: 0.128
-
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31; 373(27):2599-607.
Score: 0.128
-
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):809-17.
Score: 0.128
-
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):705-13.
Score: 0.126
-
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 01; 384(9954):1597-605.
Score: 0.117
-
The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
Score: 0.102
-
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):818-26.
Score: 0.032